200 results about "Adriamycinol" patented technology

The invention provides an atomizing agent containing stem cell exosomes as well as a preparation method and application of the atomizing agent, and belongs to the technical field of exosomes. Ferroferric oxide magnetic particles are prepared, the surfaces of the ferroferric oxide magnetic particles are modified through tannic acid, berberine and adriamycin are loaded, then the ferroferric oxide magnetic particles and the exosome secreted by adipose-derived mesenchymal stem cells are mixed, incubated and centrifuged, the mixture is added into normal saline, uniform ultrasonic dispersion is conducted, and the atomizing agent containing the stem cell exosome is prepared. The prepared atomizing agent containing the stem cell exosome is simple in preparation method and wide in raw material source, the prepared atomizing agent directly enters the lung through spray administration, the unique performance of magnetic targeting drug delivery is achieved, drugs are released in a targeted and fixed-point mode, the drug effect is improved, and the effects of efficiently promoting tumor cell apoptosis and resisting lung cancer and pneumonia are achieved.

The invention relates to the technical field of spermidine application, in particular to application of spermidine in preparation of medicine for preventing and treating doxorubicin-induced cardiotoxicity and myocardial aging. Cell proliferation experiments and mouse survival rate experiments show that spermidine can reduce death of myocardial cells and mice caused by adriamycin; a q-PCR experiment shows that spermidine can improve abnormal expression conditions of P53, P21, P16, BAX, TNF-alpha, IFN alpha, IL-10 and IL-18 in myocardial cells caused by adriamycin; a beta-galactosidase staining experiment shows that the spermidine can reduce the condition that the expression of a marker beta-galactosidase for myocardial cell senescence induced by adriamycin is increased; a Western Blot experiment shows that the spermidine can improve the condition that the P53 protein is abnormally increased due to the adriamycin; an Elisa experiment shows that spermidine can improve the condition that myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin, and the myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin. Therefore, spermidine can improve cardiotoxicity and myocardial aging induced by adriamycin.

The invention provides application of a PDLIM4 gene in preparation of a medicine for inhibiting non-small cell lung cancer proliferation, belongs to the technical field of cancer suppressor gene research, and finds that the PDLIM4 gene is highly expressed in non-small cell lung cancer tumors, and the prognosis of a patient with the highly expressed PDLIM4 gene is good; the proliferation of the non-small cell lung cancer cells overexpressed with the PDLIM4 gene is inhibited, and the proliferation of the non-small cell lung cancer cells knocked down with the PDLIM4 gene is accelerated, so that the reagent capable of realizing the overexpression of the PDLIM4 gene is confirmed to be of great significance for inhibiting the proliferation of the non-small cell lung cancer cells. The overexpression of the PDLIM4 gene in the non-small cell lung cancer cells can enhance the chemotherapy effect of the chemotherapy drug adriamycin, and can be used as a chemotherapy sensitizer. The BRD4 is an upstream regulatory factor for increasing the expression of the PDLIM4 gene in the non-small cell lung cancer, and can be used for promoting the expression of the PDLIM4 gene.

The invention discloses a fluorescence ratio type carbon dot hydrogel sensor, a preparation method thereof and application of the fluorescence ratio type carbon dot hydrogel sensor in rapid detection of doxorubicin hydrochloride. The invention discloses a fluorescence ratio type carbon dot hydrogel sensor which is characterized in that 3-aminophenol is used as a carbon source, absolute ethyl alcohol is used as a solvent, carbon dots are prepared through a one-step solvent method, the carbon dots have green fluorescence, agarose is dissolved in a mixed solution of deionized water and a phosphate buffer solution to be fully dissolved, and then the carbon dots are prepared into the fluorescence ratio type carbon dot hydrogel sensor. And adding the carbon dots into the mixed solution, fully dispersing, and cooling to obtain the fluorescence ratio type carbon dot hydrogel sensor. The sensor disclosed by the invention has the characteristics of high selectivity and high sensitivity when being used for detecting doxorubicin hydrochloride, and also has the characteristics of convenience, visibility, rapidness, portability, easiness in operation and the like.

The invention discloses a preparation method of a doxorubicin-loaded ginseng selenium polysaccharide nano-carrier with immunoregulation and liver cancer cell inhibition functions, and aims to solve the problems of toxic injury of tissues and organs and inhibition of an immune system caused by an antitumor drug doxorubicin. According to the invention, deoxycholic acid is grafted on the ginseng selenium polysaccharide, so that the ginseng selenium polysaccharide is hydrophobized and forms an amphiphilic polysaccharide polymer, and the limitations of large molecular weight, low bioavailability and the like of the ginseng selenium polysaccharide are overcome. The self-assembled ginseng selenium polysaccharide nanoparticles are used as carriers for delivering antitumor drugs, so that the self-assembled ginseng selenium polysaccharide nanoparticles have an immunoregulation effect and can effectively improve side effects such as immunosuppression caused by the antitumor drugs; and the carrier also has a pH sensitive response release characteristic, so that the targeting effect of the medicine in a tumor area is enhanced, and the innovative carrier has a good clinical application prospect.

The invention discloses a single cell activity evaluation method based on cell nucleus geometric parameters and a Bayesian framework, which comprises the following steps: establishing a HeLa cell activity gradient model through adriamycin induction, carrying out cell nucleus segmentation by adopting Cell pose 3.0 and extracting 26 geometric features, screening a high-confidence sample in combination with a Bayesian deep learning framework, and evaluating the activity of a single cell according to the high-confidence sample. And constructing a multi-modal feature fusion model to integrate geometric features and deep semantic features, and finally realizing unmarked and high-precision single cell activity evaluation. The method overcomes the limitation that a traditional technology depends on biochemical markers, has the advantages of being easy and convenient to operate, high in flux and high in interpretability, and provides an innovative technical means for tumor liquid biopsy and precise medical treatment.

The invention discloses an oxygen-enhanced fluorinated nano assembly for bidirectional amplification of tumor ferroptosis as well as a preparation method and application of the oxygen-enhanced fluorinated nano assembly, and belongs to the technical field of pharmaceutical preparation combined treatment of new auxiliary materials and new dosage forms. According to the invention, the oxygen-functionalized fluorinated adriamycin prodrug with oxygen carrying capacity is designed and synthesized for the first time, a hybrid nano-assembly composed of the disulfide-bridged fluorinated adriamycin prodrug and the ferroptosis inducer is constructed and can be used for tumor treatment, and a fluorinated functional side chain can efficiently carry oxygen to break tumor hypoxia trapping and relieve limitation of hypoxia on Sor, so that the drug can be applied to tumor treatment. DOX can activate NOXs and promote generation of ROS through supplemented oxygen as a catalytic substrate, redox balance is broken through in a two-way synergistic mode, excessive accumulation of lipid peroxide is caused, and therefore the ferroptosis treatment effect is enhanced, a new strategy and more choices are provided for drug delivery development, and the application prospect is wide. The urgent demand of the hypoxia solid tumor on efficient and diverse ferroptosis treatment strategies on preparations in clinic is met.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a combretastatin microtubule targeting agent and a preparation method and application thereof.The synthesized target compounds 9a-9l and 9m-9q have good anti-proliferative activity on tested human cancer cell lines, the representative compound 9n has the optimal anti-tumor activity, the IC50 value range is 0.09-0.51 mu M, and in addition, the target compounds 9a-9l and 9m-9q have the good anti-proliferative activity on the tested human cancer cell lines. The anti-proliferative activity of the compound 9n to cis-platinum drug-resistant cells A549 / CDDP is 121.45 times that of cis-platinum, the anti-proliferative activity of the compound 9n to adriamycin drug-resistant cells MCF-7 / DOX is 74.88 times that of adriamycin, and the toxicity of the compound 9n to human normal hepatocytes (HL-7702) is low. In a HepG-2 xenotransplantation tumor model, the in-vivo anti-tumor activity of the compound 9n is superior to that of a positive drug CA-4, and the compound 9n has no obvious systemic toxicity. Therefore, the compound has the potential purpose of targeted treatment of liver cancer.

The invention discloses a 3D bio-printing sustained-release microneedle patch used after brain glioma surgery and a preparation method thereof.The microneedle patch is prepared by compounding GFD nano-enzyme and a hydrogel base material, the GFD nano-enzyme is gambogic acid-iron-adriamycin nano-enzyme, and the hydrogel base material is a hydrogel base material. The hydrogel base material is composed of photo-crosslinking gelatin (GelMA), methacrylic hyaluronic acid (HAMA), a photoinitiator and an ultraviolet absorbent, the microneedle patch is of a conical microneedle array structure, the interior of the microneedle patch is of a porous structure, and GFD nano-enzyme is evenly distributed in microneedles. The application potential of the existing 3D biological printing and nano-enzyme technology and the technical advantages of 3D biological printing are adopted, by means of the 3D biological printing technology with high-dimensional manufacturing precision, the microneedle array structure is designed and printed in a customized mode according to the irregular shape of the tumor residual cavity of a patient, complete attachment to the wall of the residual cavity is achieved, and the dead cavity effect is solved; meanwhile, the technology can accurately regulate and control the shape, the size and the drug loading capacity of the microneedle, and provides possibility for personalized treatment.

The invention discloses an adriamycin-tetravalent platinum drug-norcantharidin three-drug combined nano-drug as well as a preparation method and application thereof, and belongs to the technical field of medical materials. A tetravalent platinum drug modified by demethylated cantharidin and adriamycin are used as raw materials, a novel nano-drug is constructed through Cu < 2 + > coordination, and then the nano-drug combining adriamycin, the tetravalent platinum drug and demethylated cantharidin is prepared by polymerizing polydopamine with a mild photo-thermal effect. The polymer has the capacity of controllably releasing drugs under acidity and reduction, can realize photo-thermal conversion under laser irradiation to generate a mild photo-thermal effect, has a better tumor cell killing effect, has the capacity of consuming glutathione and generating hydroxyl radicals, can enter cancer cells in an endocytosis mode and release DOX, and can be used for killing tumor cells. And a new thought is provided for multi-drug combination and chemotherapy-chemokinetics therapy-photothermal therapy multi-mode combined therapy.

The invention provides an application of a selenium-containing preparation in a drug for antagonizing NK cell injury caused by chemotherapy and a drug for antagonizing cisplatin or adriamycin induced NK cell injury. At present, common cancer treatment methods include operative treatment, chemotherapy, radiotherapy and immunotherapy, and chemotherapy is still a main treatment means for most advanced malignant tumors. Meanwhile, chemotherapy has an inhibition effect on an immune system, which is mainly manifested in that the immune system of a patient is damaged and T cells and NK cells are reduced due to direct killing of chemotherapy drugs on immune cells, so that the normal physiological function of the immune system is influenced, tumor cells can be induced to generate immune tolerance, and the metastasis of the tumor cells is accelerated. The selenium-containing preparation is applied to antagonism of induced damage of cis-platinum or adriamycin to NK cells, damage of cis-platinum or adriamycin to NK cells can be antagonized, and effectiveness of chemotherapy and immunotherapy is improved.

The invention belongs to the technical field of drug co-delivery, and particularly relates to a nano-platform based on attenuated bacterial outer membrane vesicles and capable of achieving co-delivery of siRNA and adriamycin and a preparation method of the nano-platform. The preparation method comprises the following steps: synthesizing an ROS response type cationic polymer PTP; the preparation method comprises the following steps: preparing aptamer-DOX; preparing an ROS (reactive oxygen species) response type positive electric nano core PTP / 47aD; extracting and purifying the [delta] msbB OMVs; synthesizing a target functional unit DSPE-PEG2k-Angiopep-2 (Distearoyl Phosphate Polyethylene Glycol 2k-Angiopep-2); finally, the ROS response type co-delivery nano platform AO (at) PTP / 47aD is prepared and obtained. The co-delivery nano-platform prepared by the invention is relatively small in particle size, uniform in morphology and relatively high in biological safety, and has no obvious damage to various tissues and visceral organs. The glioblastoma immunopotentiator can be used as a general platform for gene delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and can comprehensively overcome immune resistance of glioblastoma.

The embodiment of the invention provides a method for constructing a vascular organoid by using human pluripotent stem cells and application of the vascular organoid, and relates to the technical field of medicine. The method for constructing the vascular organoid by using the human pluripotent stem cells comprises the following steps: comprehensively analyzing the quality of hPSCs (human pluripotent stem cells) for differentiating the vascular organoid through morphological observation, RT-qPCR (real-time quantitative polymerase chain reaction) and AP (access point) staining experiments; repeating a differentiation experiment to test the stability of the optimized vascular organoid construction scheme; identifying the vascular organs constructed by the optimization scheme through RT-qPCR (Reverse Transcription-Quantitative Polymerase Chain Reaction) and integral and slice immunofluorescence experiments; the adriamycin is randomly divided into a DMSO (dimethylsulfoxide) control group, a 0.5 mu M group and a 5 mu M group, and the influence of the adriamycin on human vascular organs is analyzed from the transcriptional level through an RT-qPCR experiment. Compared with a traditional vascular organ construction method, the construction method provided by the invention uses fewer reagents and consumables, and the process is more simplified; the vascular organ construction method is feasible and effective, and stable human vascular organs similar to human microvascular cell components and structures are constructed.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a novel tubulin and metalloproteinase double-target inhibitor as well as a preparation method and application of the novel tubulin and metalloproteinase double-target inhibitor. A novel tubulin and metalloproteinase double-target inhibitor is obtained as a compound with a targeting function. A verification result shows that the synthesized target compound shows good anti-proliferative activity on tested cancer cells, 15j has the optimal anti-tumor activity, the IC50 value range of the target compound is 0.154-0.296 mu M, and the tumor inhibition rate of the target compound on human lung cancer transplantation tumors is 74.7% (20 mg / kg). Besides, the anti-proliferative activity of the 15j to cis-platinum drug-resistant cells A549 / CDDP is 136.70 times that of the cis-platinum, the anti-proliferative activity of the 15j to adriamycin drug-resistant cells MCF-7 / DOX is 71.14 times that of the adriamycin, and the toxicity of the 15j to human normal cells (LO2 and MCF-10A) is lower than that of positive drugs such as the cis-platinum, the adriamycin and the paclitaxel. Therefore, the compound has the potential purpose of targeted treatment of lung cancer.

The invention discloses an application of a meroterpenoid compound I in preparation of an anti-heart failure medicine. The meroterpenoid I separated and purified from marine fungi Aspergillus terreus GZU-311 is used for treating a mouse heart failure model induced by adriamycin or coronary artery left anterior descending branch ligation, and it is found that the meroterpenoid I can improve the heart function of a mouse, reduce myocardial cell damage, inhibit myocardial connective tissue thickening and improve myocardial cell arrangement disorder, and the meroterpenoid I can be used for treating the heart failure of the mouse induced by adriamycin or coronary artery left anterior descending branch ligation, so that the meroterpenoid I can be used for treating the heart failure of the mouse induced by adriamycin or coronary artery left anterior descending branch ligation. Inflammatory cell infiltration is reduced, and the effect of resisting heart failure is achieved. Therefore, the invention provides the application of the meroterpenoid I in preparing the heart failure resisting medicine. According to the invention, medicine source molecules for treating heart failure are enriched, and development and clinical treatment of anti-heart-failure medicines are facilitated.

The invention discloses a preparation method and application of a copper oxide coated adriamycin nano-material, the prepared drug-loaded nano-material has good antitumor activity, and the preparation scheme comprises synthesis of Cu2O nano-particles, synthesis of Cu2O-NH2 nano-particles and drug loading. The copper oxide coated doxorubicin nano-material prepared by the invention can effectively load doxorubicin medicine into nano-particles, so that the medicine transfer efficiency is improved, and the effect of the medicine in vivo is enhanced. The nano material disclosed by the invention can accurately regulate and control the release rate of adriamycin under different buffer solution pH values or different time points, so that the sustained release of the medicine under specific conditions is realized, and the curative effect of the medicine is improved. By modifying the surface of copper oxide, targeted delivery of the medicine can be realized, the medicine can be more accurately delivered to breast cancer cells, the influence on normal cells is reduced, the treatment effect is improved, and the effective service life of the medicine is prolonged.

The invention relates to the technical field of liposome preparation, and particularly discloses a nano liposome and a preparation method thereof.The method comprises the steps that distearoyl phosphatidyl ethanolamine, cholesterol, hydroxyl-terminated polyethylene glycol and mPEG-Hyd-PEG-SH are dissolved in a mixed solvent, and a lipid film is formed through rotary evaporation; hydrating with a PBS (Phosphate Buffer Solution) containing ammonium sulfate, and carrying out ultrasonic treatment to obtain primary emulsion; a doxorubicin solution is added for incubation, and drug loading is completed; the CD44 antibody and the drug-loaded liposome are coupled in a catalytic system, and are homogenized by a spiral microreactor. The problems of high immunogenicity, insufficient targeting, non-uniform particle size, uncontrollable drug release and complex preparation process of the existing PEG nano-liposome are solved, and the PEG nano-liposome has the advantages of low immunogenicity, high targeting, uniform and stable particle size, drug response release and easiness in large-scale production.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

The invention relates to the technical field of artificial lenses, in particular to a modified artificial lens and a preparation method and application thereof. The modified intraocular lens is characterized in that a PHEMA-copolymer film-serine polymer intraocular lens is used as a carrier, and adriamycin is loaded on the surface of the carrier. The modified intraocular lens has good physical barrier and biological inhibition effects, can avoid accumulation of proteins and lipids in tears, can avoid generation of bacterial infection complications, can prevent adhesion of lens epithelial cells, can block DNA replication and transcription processes of the lens epithelial cells, can inhibit proliferation of the lens epithelial cells, and can improve the lens epithelial cell proliferation rate. The prepared nano-material can induce apoptosis of lens epithelial cells, has an excellent antibacterial effect and good biocompatibility, and can prevent the occurrence of posterior cataract.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention relates to the technical field of biological medicines, in particular to an anti-tumor compound as well as a preparation method and application thereof. The nano-diamond cannot effectively kill tumor cells due to good biocompatibility, and the ferrocene with an aromatic ring structure is combined with the nano-diamond, so that a good anti-tumor effect can be fully exerted. The TAT-PEG-PLGA has the advantages that the TAT-PEG-PLGA is high in membrane penetrating capability, water solubility, biocompatibility, stability and targeting property; the TAT-PEG-PLGA with adsorption force on the surface is used for loading the ferrocene-nano-diamond and the adriamycin to obtain the anti-tumor compound, so that the ferrocene-nano-diamond and the adriamycin can effectively enter tumor cells to jointly play an anti-tumor effect. The obtained anti-tumor compound can effectively inhibit the activity of melanoma cells A375, is an effective tumor inhibitor, and can provide a new treatment strategy and choice for tumor treatment.

The method comprises the following steps: taking red ginseng, radix ophiopogonis and schisandra chinensis, carrying out water extraction and freeze drying to obtain freeze-dried powder, taking the freeze-dried powder, adding distilled water to dissolve the freeze-dried powder, adding the dissolved freeze-dried powder to a macroporous adsorption resin column, carrying out gradient elution with water, a 20% ethanol aqueous solution, a 50% ethanol aqueous solution and a 75% ethanol aqueous solution in sequence, and carrying out vacuum concentration to obtain the effective part of the pulse-activating decoction. From the beginning of sample loading, collecting every 300mL of effluent as a fraction, and collecting the fractions Fr1-Fr16; the chromatographic characteristics are analyzed, fractions with the same chromatographic characteristics are combined, the fractions Fr15-Fr16 are combined into a component yf-10, and the component yf-10 is the effective part of the pulse-activating decoction. According to the effective part disclosed by the invention, toxic parts are removed, so that H9c2 cell injury caused by adriamycin can be protected in a more effective, more stable and lower-toxicity manner, and the application of the component yf-10 in preparation of medicines for treating myocardial cell injury is prompted.

The invention discloses application of gnetum alcohol in treatment of adriamycin cardiomyopathy and diseases caused by adriamycin cardiomyopathy. The invention provides the application of the Gnetol or the pharmaceutically acceptable salt thereof in preparation of the medicine for preventing or treating diseases caused by adriamycin cardiomyopathy for the first time. The invention finds that in-vitro treatment of Gnemol can obviously inhibit rat H9C2 myocardial cell injury; when intraperitoneal injection of Gnetol is used for preventing or treating mice with adriamycin cardiomyopathy caused by intraperitoneal injection of adriamycin, the Gnetol is found to obviously relieve the adriamycin cardiotoxicity of the mice and improve the cardiac function. In-vitro and in-vivo studies find that Gnerol has a huge potential in treatment of adriamycin cardiomyopathy, and can be developed as a novel anti-adriamycin cardiomyopathy drug, thereby providing a novel approach and means for treatment of adriamycin cardiomyopathy. Meanwhile, the invention provides a brand new choice and thought for the current anti-adriamycin cardiomyopathy medicine.

The invention discloses a method for producing high-purity doxorubicin through fermentation of streptomyces peucedanum var. Peucedanum X121-56-2 and in-situ extraction of LX-20 resin, which comprises the following steps: preparing a high-density seed solution through a specific seed culture medium and a culture process, and then inoculating the high-density seed solution into a fermentation culture medium containing a composite carbon and nitrogen source and LX-20 macroporous adsorption resin; and fermenting under the conditions of controlled temperature, pH, ventilation and dissolved oxygen. In the fermentation process, adriamycin is adsorbed by LX-20 resin in situ, the yield is effectively increased, and the extraction process is simplified. The specific strain is combined with the LX-20 resin technology for the first time, the adriamycin yield can reach 530 mg / L at the maximum under the 15L tank scale, the purity of a crude product directly extracted from the resin can reach 58%, and the method has the outstanding advantages of being high in yield and purity, low in cost, easy to amplify and the like.

The application discloses application of falcarinol-7-methyl ether and derivatives thereof in preparation of medicines and functional foods for delaying aging or immune regulation. In the application, the falcarinol-7-methyl ether and derivatives thereof are derived from falcarinol-7-methyl ether, and can effectively delay replicative senescence of mesenchymal stem cells, inhibit expression of aging-related markers of mouse liver and lung induced by adriamycin, improve grip strength of the mouse, enhance muscle function, and promote proliferation of T cells separated from human peripheral blood mononuclear cells, and have an immune regulation effect. Therefore, the falcarinol-7-methyl ether and derivatives thereof have good effects of improving telomerase activity, anti-aging and immune regulation, and can be developed into anti-aging or immune regulation products.

The application discloses application of a heteroterpene compound I in preparation of a heart failure resisting drug. The heteroterpene compound I is obtained by separation and purification from a marine fungus Aspergillus terreus GZU-311, and is used to treat a mouse heart failure model induced by adriamycin or left anterior descending coronary artery ligation, and it is found that the heteroterpene compound I can improve the heart function of the mouse, reduce myocardial cell damage, inhibit myocardial connective tissue thickening, improve myocardial cell arrangement disorder, reduce inflammatory cell infiltration, and has an effect of resisting heart failure. Therefore, the application provides application of the heteroterpene compound I in preparation of a heart failure resisting drug. The application enriches drug source molecules that can be used for treating heart failure, and is helpful to development of an anti-heart failure drug and clinical treatment.

The application discloses a kind of degradable organic-inorganic hybrid nanoparticles based on calcium carbonate and preparation method thereof, the preparation method of the application uses calcium carbonate and amphiphilic block copolymer as raw material, uses amphiphilic block copolymer as organic matrix, and uses calcium carbonate aqueous solution as inorganic matrix, water-soluble drug doxorubicin hydrochloride (DOX·HCl) is wrapped in nanoparticle, and a kind of calcium carbonate-based hybrid nanoparticle is prepared using stirring mixing technology.The nanoparticle prepared by the application has moderate particle size, uniform particle size distribution, good biocompatibility and biodegradability, and is expected to become a novel drug delivery carrier.

The invention relates to the technical field of electrochemical biosensors, in particular to preparation of a ratio type doxorubicin electrochemical aptamer sensor based on a single signal molecule, the sensor realizes double current signal output through the single signal molecule, and calibration-free rapid detection of doxorubicin is realized by utilizing a ratio signal. The method comprises the following specific steps: fixing an adriamycin aptamer modified with methylene blue on the surface of a gold electrode; performing electrochemical scanning in a buffer solution system (such as a 1 * PBS solution) by adopting a square wave voltammetry to obtain two current peak signals; and calculating the ratio of the two current peak signals to determine the doxorubicin concentration. According to the method, the sensitivity and the accuracy of detection are improved, the influence of environmental factors and sensor manufacturing changes on a detection result is reduced, and the calibration-free rapid detection of the concentration of the adriamycin is realized. The sensor can keep signal stability in long-time continuous testing, is suitable for rapid detection of adriamycin and has a wide application prospect.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of an anti-breast cancer medicine, and relates to the technical field of biological medicine and traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 to 60 parts of radix acanthopanacis semticosi, 30 to 60 parts of fructus ligustri lucidi, 30 to 60 parts of rhizoma bolbostemmae, 30 to 60 parts of caulis spatholobi, 30 to 60 parts of resina liquidamberis, 30 to 60 parts of tabasheer, 30 to 60 parts of gynura procumbens, 30 to 60 parts of aspongopus, 30 to 60 parts of pecteilis sumadai, 30 to 60 parts of thlaspi arvense, 30 to 60 parts of herba dendrobii and 10 to 30 parts of fructus ziziphi jujubae. The traditional Chinese medicine composition has the effects of strengthening the body resistance to eliminate pathogenic factors, detoxifying, removing stasis, activating blood, reducing phlegm, tonifying qi and nourishing yin. On the in-vitro level, the traditional Chinese medicine composition can remarkably inhibit proliferation, migration and invasion of BT549 and 4T1 cells at different concentrations. On the in-vivo level, the traditional Chinese medicine composition can significantly inhibit the growth speed, volume and quality of tumors, and shows an excellent tumor inhibition effect. And the anti-tumor effect of the compound can be improved after the compound is combined with adriamycin. The traditional Chinese medicine composition is expected to be further popularized and applied as an anti-breast cancer medicine.